8-K: QHSLab Reports Strong Revenue Growth, Debt Reduction

QHSLab Inc. announced unaudited financial and operational updates, highlighting 32% revenue growth, positive operating income, and significant convertible debt reduction ahead of its January 2026 investor session.

Summary

• Unaudited revenue for the nine months ended September 30, 2025, reached $1.99 million, representing a 32% increase year-over-year.
• Gross profit for the same period was $1.32 million, reflecting a gross margin of approximately 66%.
• Net operating income before interest was $95,738.
• Cash at bank as of December 31, 2025, was approximately $630,000.
• Outstanding convertible debt was reduced from approximately $1.4 million to $20,000 during the fourth quarter of 2025.
• The elimination of convertible debt is expected to reduce annual interest expense by more than $250,000 on a forward-looking basis.
• The company has 13,418,899 shares of common stock outstanding, of which approximately 2,429,525 shares constitute the public trading float.
• Approximately 2,301,565 restricted common shares, issued in connection with recent debt conversions, equity financings, and preferred share dividend payments, are subject to Rule 144 restrictions.

Sentiment

Score: 8

Explanation: The filing presents strong positive financial and operational updates, including significant revenue growth, positive operating income, substantial debt reduction, and an expectation of full-year net income. These factors indicate a very positive trajectory for the company.

Positives

• Achieved 32% year-over-year revenue growth, reaching $1.99 million for the nine months ended September 30, 2025.
• Reported a strong gross margin of approximately 66% with $1.32 million in gross profit.
• Generated positive net operating income before interest of $95,738.
• Significantly reduced outstanding convertible debt from approximately $1.4 million to $20,000.
• Anticipates an annual interest expense reduction of more than $250,000 due to debt elimination.
• Exited 2025 in a cash-flow-positive operating position.
• Ended 2025 with a healthy cash balance of approximately $630,000.
• Management expects to report net income after interest, amortization, and depreciation for the full year ended December 31, 2025.

Negatives

• Approximately 2,301,565 restricted common shares, issued from recent debt conversions, equity financings, and preferred share dividend payments, are subject to Rule 144 restrictions and a six-month holding period, potentially leading to future dilution when they become unrestricted.

Risks

• The timing of the introduction of new products.
• Inherent discrepancy in actual results from estimates, projections, and forecasts made by management.
• Regulatory delays.
• Changes in government funding and budgets.
• General economic conditions not within the company's control.

Future Outlook

Management believes the company is positioned for improved operating leverage entering 2026 and expects to report net income after interest, amortization, and depreciation for the year ended December 31, 2025, subject to completion of year-end financial close and audit procedures. This disclosure is provided for transparency ahead of investor discussions and does not constitute formal guidance.

Management Comments

• Management believes the Company exited 2025 in a cash-flow-positive operating position.
• Management believes the Company is positioned for improved operating leverage entering 2026 and expects to report net income after interest, amortization, and depreciation for the year ended December 31, 2025, subject to completion of year-end financial close and audit procedures.

Industry Context

QHSLab operates in the digital health infrastructure sector, providing preventive screening, assessment, and workflow solutions for primary care practices. The reported revenue growth and move towards profitability align with broader industry trends favoring scalable, documented, and reimbursable digital health solutions that extend care beyond traditional exam rooms, particularly for underdiagnosed conditions. This positions QHSLab to capitalize on the increasing demand for efficient and technology-driven healthcare delivery.

Stakeholder Impact

• Shareholders: Positive impact due to strong revenue growth, improved profitability, significant debt reduction, and expected net income, which could lead to increased share value. There is a potential for future dilution from restricted shares becoming unrestricted.
• Creditors: Positive impact due to substantial reduction in convertible debt, improving the company's financial stability and creditworthiness.
• Employees: Positive impact from a growing and more financially stable company, potentially leading to job security and growth opportunities.
• Customers (Primary Care Practices): Continued and potentially expanded service offerings from a financially healthier QHSLab, enhancing their ability to deliver preventive care.

Next Steps

• Conduct a scheduled investor discussion on January 6, 2026.
• Complete year-end financial close and audit procedures for the year ended December 31, 2025.
• Public resale of restricted common shares after the applicable six-month holding period has elapsed and other Rule 144 conditions are satisfied.

Key Dates

Recommendation

The company demonstrates robust financial health with 32% revenue growth, positive operating income, and a significant reduction in convertible debt, which will substantially lower future interest expenses. Management expects to achieve net income for the full year 2025 and exited the year cash-flow positive. These factors indicate strong operational execution and a favorable financial trajectory, making it an attractive investment opportunity. The only minor concern is the future potential for dilution from restricted shares, but the current positive momentum significantly outweighs this.

Keywords

QHSLab, USAQ, digital health, healthcare technology, financial update, revenue growth, convertible debt, operating income, cash flow, SEC filing, 8-K, investor session